FULL CIRCLES THERAPEUTICS

Full Circles Therapeutics, formerly known as Stellate Biotherapeutics, operates in the biotechnology sector with a focus on genomic medicine. The company has developed a groundbreaking platform called GATALYST, which enables the insertion of any genetic sequence of any size at any location within the human genome of disease-relevant cells. This innovative technology is designed to treat severe genetic diseases and cancer without the use of viral vectors, which are commonly used in traditional gene therapies.

Full Circles Therapeutics primarily serves patients suffering from severe genetic disorders and various forms of cancer. The company operates globally, aiming to provide curative genomic medicines that offer long-term solutions to these debilitating conditions. The business model revolves around the discovery, development, manufacturing, and commercialization of novel genomic therapies. Revenue is generated through the sale of these therapies, partnerships with other biotech firms, and potential licensing agreements.

The company's mission is to revolutionize the field of genomic medicine by offering safer and more effective treatments. By eliminating the need for viral vectors, Full Circles Therapeutics aims to reduce the risks associated with gene therapy and improve patient outcomes.

Keywords: genomic medicine, GATALYST platform, viral-free, genetic diseases, cancer treatment, biotechnology, gene insertion, curative therapies, global market, innovative technology.